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Abstract The transient receptor potential ankyrin 1 (TRPA1)
channel is a nonselective cation channel belonging to the su-
perfamily of transient receptor potential (TRP) channels. It is
predominantly expressed in sensory neurons and serves as an
irritant sensor for a plethora of electrophilic compounds.
Recent studies suggest that TRPA1 is involved in pain, itch,
and respiratory diseases, and TRPA1 antagonists have been
actively pursued as therapeutic agents. Here, we review the
recent progress, unsettled issues, and challenges in TRPA1
research and drug discovery.
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Introduction
Transient receptor potential ankyrin 1 (TRPA1) is one of the
28 members of the transient receptor potential (TRP) channel
family and the sole member of the TRPA subfamily in mam-
mals. Like all TRP channels, TRPA1 possess a tetrameric
structure with a single pore present at the central axis. Each
subunit contains six transmembrane alpha helices (labeled
S1–S6) and intracellular N-terminal and C-terminal domains
(see Fig. 1). The pore-forming selectivity filter is positioned
between the S5 and S6 transmembrane helices. TRPA1 is
unusual among mammalian TRP channels in having a very
long ankyrin repeat within the N-terminal domain (14–18
ankyrin repeats depending on species). TRPV and TRPC
channels also have N-terminal ankyrin repeats, although they
are much shorter (three to six repeats). TRPA1 is permeable to
both monovalent and divalent cations, and therefore, TRPA1
is capable of depolarizing the membrane and initiating Ca2+
signaling in the cells it is expressed.
Expression pattern
TRPA1 is highly expressed in small- and medium-sized
peptidergic primary afferent somatosensory neurons present
in sensory ganglia-containing nociceptors—the dorsal root
ganglia (DRGs), the trigeminal ganglia (TGs), and the nodose
ganglia (NGs) (Nagata et al. 2005). Depending on different
reports, the fraction of DRG neurons expressing TRPA1
varies from 3.6 to 56.5 % (Story et al. 2003; Nagata et al.
2005; Bautista et al. 2006; Kwan et al. 2006; Niforatos et al.
2007), with the most commonly reported values being around
30 %. The capsaicin receptor TRPV1 appears to be co-
expressed in most if not all TRPA1-expressing DRG neurons
(Bautista et al. 2006; Anand et al. 2008). This finding is fur-
ther supported by the observation that mustard oil-induced
nocifensive behavior is eliminated in mice where the central
terminals of TRPV1-expressing DRG neurons have been ab-
lated by intrathecal injection of capsaicin (Shields et al. 2010).
In addition to TRPV1, TRPA1-expressing nociceptors also
express calcitonin gene-related peptide (CGRP), substance P,
and the bradykinin receptor, which are key mediators/
transmitters in nociceptive signaling (Jordt et al. 2004; Obata
et al. 2005; Bautista et al. 2006).
TRPA1 expression outside of nociceptive neurons has been
reported by many groups, though the results do not always
have the same level of consistency as seen in DRG and TG
neurons. Nonetheless, expression in such cells represents po-
tential locations where selective TRPA1 antagonists might
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have on-target effects outside of pain. Hair cells in the inner
ear were reported to express TRPA1 at both the RNA and
protein level as determined by in situ hybridization and im-
munohistochemistry, respectively (Corey et al. 2004; Nagata
et al. 2005). As such, TRPA1was proposed to be a component
of the hair cell tip-link mechanotransducer channel necessary
for auditory transduction. However, further experiments with
TRPA1 knockout (KO) mice demonstrated that TRPA1 ap-
pears not to contribute to hair cell transduction or auditory
function in vivo (Bautista et al. 2006; Kwan et al. 2006).
Sympathetic neurons such as those of the superior cervical
ganglion (SCG) have been reported to express TRPA1
(Smith et al. 2004), though other groups have failed to detect
significant levels of TRPA1 RNA in the SCG (Nagata et al.
2005; Munns et al. 2007). Myenteric neurons and enterochro-
maffin cells (as well as some nonneuronal epithelial cells) in
the small and large intestine have also been proposed to ex-
press TRPA1 based on immunohistochemistry and RT-PCR
(Anand et al. 2008; Nozawa et al. 2009; Poole et al. 2011;
Kono et al. 2013). Furthermore, treatment of enterochromaffin
cells with TRPA1 agonists induces serotonin release, and
treatment of the isolated guinea pig ileum with allyl isothio-
cyanate (AITC) induces 5-HT3-receptor-mediated gastroin-
testinal smooth muscle contractions. TRPA1 agonists have
been further shown to delay gastric emptying in rats through
this pathway (Doihara et al. 2009). However, it is not clear
whether TRPA1 antagonists would have deleterious effects on
gut motility.
Nonneuronal expression of TRPA1 has been reported by
many groups. In the lung, besides its expression in innervating
sensory fibers, TRPA1 has been detected in several
nonneuronal cell types including lung fibroblasts, alveolar ep-
ithelial cells, and lung smooth muscle cells in both human and
mouse (Mukhopadhyay et al. 2011; Nassini et al. 2012),
though only very low levels of TRPA1 RNA in the mouse
and human lung were detected in other reports (Jaquemar
et al. 1999; Story et al. 2003; Jang et al. 2012) (author’s un-
published data). In skin, TRPA1 has been found in several cell
types including melanocytes, keratinocytes, and fibroblasts
(Anand et al. 2008; Atoyan et al. 2009; Tsutsumi et al.
2010), and therefore, it has been hypothesized that TRPA1
plays a role in the regulation of keratinocyte differentiation
and inflammation in the skin. TRPA1 has been found in epi-
thelial cells lining the urinary tract (Streng et al. 2008; Gratzke
et al. 2010) in addition to sensory fibers innervating the uri-
nary tract (Andrade et al. 2006); therefore, TRPA1 may play a
role in urinary micturition. It has also been found that TRPA1
is expressed in vascular endothelial (Gratzke et al. 2009; Qian
et al. 2013) and in basal/subepithelial cells of the human pros-
tate gland (Gratzke et al. 2010). Beta islet cells of the pancreas
have been shown to express TRPA1, and activation of TRPA1
in these cells results in insulin release (Cao et al. 2012).
Astrocytes in the brain appear to express TRPA1, and
astrocyte TRPA1 channels appear to play an important role
in calcium homeostasis and the regulation of the GABA trans-
porter GAT-3 (Shigetomi et al. 2012), albeit at relatively lower
lever than that of DRG neurons. As TRPA1 antagonists are
developed for treating pain and other disorders, close exami-
nation of potential on-target side effects resulting from the
expression of TRPA1 outside of the targeted tissue (e.g.,
DRG and TG) should be considered.
Modulation of TRPA1
Endogenous agonists
In order for TRPA1 to be regarded as a good target for pain
and other disorders, it should be active in the context of some
pathological state. The best-known activators of TRPA1, how-
ever, are a set of exogenous electrophilic agonists that form
covalent adducts with cysteine and lysine residues contained
within the N-terminal domain (Figs. 1 and 2). Examples of
such covalent agonists are AITC from wasabi (Bandell et al.
2004; Jordt et al. 2004), cinnamaldehyde from cinnamon ex-
tracts (Bandell et al. 2004; Jordt et al. 2004), allicin from garlic
extract (Bautista et al. 2005; Macpherson et al. 2005), acrolein
in diesel exhaust (Bautista et al. 2006), and other noxious
substances such as tear gases (Bessac et al. 2008). TRPA1
can therefore clearly function as a nociceptive chemosensor
and may have evolved in part for this purpose. Endogenous
agonists have also been found and have led to the idea that

















Fig. 1 Structure of the TRPA1 channel. The TRPA1 channel shares the
overall architecture of voltage-gated ion channels. It is a homotetramer
with each subunit containing six transmembrane helices and intracellular
N- and C-termini (as shown). The transmembrane helices are labeled S1–
S6 with S1–S4 representing the ancestral voltage-sensing domain (VSD)
and S5–S6 forming the central pore and selectivity filter. The reactive
lysine and cysteine residues are shown within the N-terminal domain,
along with the N-terminal ankyrin repeats. Please note N855S, the residue
mutated in familial episodic pain syndrome (FEPS), is shown on the
intracellular end of S4 based on recent electron cryo-microscopy structure
of TRPV1 (Liao et al. 2013) and comparison between TRPA1 and
TRPV1 hydropathy plots, and the putative Ca++ binding region is shown
within the C-terminus
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and potentially during certain pathological states. Examples of
endogenous agonists are oxidized lipids such as 4-hydroxy-2-
nonenal (4-HNE) (Taylor-Clark et al. 2008a; Trevisan et al.
2014a), 4-oxo-nonenal (Andersson et al. 2008), 5,6-
eposyeicosatrienoic acid (5-6-EET) (Sisignano et al. 2012),
15-deoxy-Δ12,14-prostaglandin J2 (Andersson et al. 2008;
Cruz-Orengo et al. 2008), and 8-iso-prostaglandin A2
(Taylor-Clark et al. 2008b), nitrated lipids such as nitrooleic
acid (9-OA-NO2) (Taylor-Clark et al. 2009), general long-
chain polyunsaturated fatty acids (Motter and Ahern 2012),
and small endogenous reactive molecules such as H2O2
(Andersson et al. 2008). In this manner, TRPA1 may be
viewed as a sensor for oxidative stress since endogenous li-
gands can accumulate and activate the channel directly, there-
by contributing to inflammatory pain in a TRPA1-dependent
manner. Oxidative stress has also been proposed to play an
important role in several rodent models of neuropathic pain
(Kim et al. 2004; Naik et al. 2006), and recently, TRPA1 has
been found in some cases to play an important role in linking
the presence of oxidative stress to inflammatory and neuro-
pathic pain (Trevisan et al. 2013a; Trevisan et al. 2013b;
Trevisan et al. 2014b). Additionally, methylglyoxal, a reactive
metabolite that accumulates intracellularly in diabetes
(Brownlee 2001; Nakayama et al. 2008) and chronic kidney
disease (Nakayama et al. 2008), is able to directly activate
TRPA1 resulting in a painful neuropathy in mice (Eberhardt
et al. 2012; Andersson et al. 2013). It is therefore possible that
methyglyoxal contributes to diabetic neuropathic pain and the
neuropathic pain present in patients with chronic kidney dis-
ease. Another classes of potentially physiologically relevant
endogenous TRPA1 agonists are the small endogenous
gasotransmitters NO (Takahashi et al. 2008) and H2S
(Andersson et al. 2012). While these have been proposed to
activate TRPA1 in vivo, the concentrations necessary to in-
duce TRPA1 activation are higher than would likely occur
physiologically. Recently, nitroxyl anion (HNO), which can
be formed via chemical reaction between NO and H2S, has
been shown to directly activate TRPA1 at physiologically rel-
evant concentrations and may play an important role in local
and systemic blood flow control (Eberhardt et al. 2014). This
observation may open new therapeutic strategies for targeting
cardiac failure but also indicates new potential adverse effects
with TRPA1 blockade.
Calcium
Intracellular calcium can modulate TRPA1 by both directly
activating the channel as well as enhancing activation by ag-
onists (e.g., AITC, cinnamaldehyde, and icilin) (Doerner et al.
2007; Zurborg et al. 2007; Wang et al. 2008b) (Fig. 2). In fact,
activation by icilin may require the presence of elevated intra-
cellular calcium (Doerner et al. 2007). Additionally, calcium
influx is also able to rapidly inactivate the channel.
Inactivation may occur at significantly higher local intracellu-
lar calcium concentrations than is required for calcium-
dependent enhancement of activation (Wang et al. 2008b).
At the molecular level, the mechanisms for such actions are
not entirely understood. Calmodulin (CaM) appears not to be
involved based on experiments co-expressing a dominant-
negative CaM mutant and CaM antagonists (Doerner et al.
2007; Zurborg et al. 2007). An EF-hand-like region was iden-
tified within the ankyrin repeat of the N-terminal domain, but
mutagenesis to disrupt the EF-hand resulted in inconsistent
results. Specifically, mutation of the proposed essential EF-
hand residue (D468A) did not alter calcium sensitivity
(Doerner et al. 2007; Zurborg et al. 2007); the mutation of a
nearby residue (L474A) was found to eliminate calcium sen-
sitivity by one group (Doerner et al. 2007), but this result
could not be reproduced by another group (Wang et al.
2008b). Adding more complexity to the matter, a third group
identified an separate domain within N-terminal ankyrin re-
peat region (outside the EF-hand-like region) as essential for
calcium-dependent inactivation (Cordero-Morales et al.
2011), while a fourth group suggested that acidic residues in
the C-terminal domain form a calcium binding site similar to
the calcium binding site present in BK potassium channels
(Sura et al. 2012) (Fig. 2).
Protons
Rodent DRG neurons are sensitive to low pH produced during
tissue acidosis due to the presence of H+-sensitive ion chan-
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Fig. 2 Modulation of TRPA1. TRPA1 is modulated by in multiple ways
and represents an integrator of nociceptive signals. Agonists bind to the
channel (most but not all within the N-terminal domain) and result in
direct activation. PIP2 functions as an endogenous inhibitor which is
removed by GPCR-dependent activation of PLC. PLC also liberates
IP3, resulting in release of Ca
++ from intracellular stores. Ca++, either from
stores or from influx through other channels such as TRPV1, positively
modulates TRPA1 via an intracellular binding site which has not been
fully elucidated. Cold and mechanical forces can also activate TRPA1 via
mechanisms that are not well understood
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recently been shown that human TRPA1, but not rodent
TRPA1 or even rhesus monkey TRPA1, can be directly acti-
vated by protons (de la Roche et al. 2013). Proton activation
occurs over a pH range from 6.0 to 7.0 with a midpoint of
around pH 6.5, which is within the physiological pH range
that would be expected to occur during tissue acidosis. It is
currently unclear whether this observed pH dependence of
human TRPA1 plays an important role in vivo.
GPCR modulation
G protein-coupled receptors (GPCRs) such as the bradykinin
receptor, the protease-activated receptor 2 (PAR2), the bile
acid receptor TGR5, the thymic stromal lymphopoietin
(TSLP) receptor, and the MAS-related GPCRs MrgprA3 and
MrgprC11 have been shown to modulate the function of
TRPA1 in cultured DRG neurons (Bandell et al. 2004; Dai
et al. 2007;Wang et al. 2008a;Wilson et al. 2011;Wilson et al.
2013b; Lieu et al. 2014) (Fig. 2). Activation of these GPCRs
results in the direct activation of TRPA1 and/or sensitization
of TRPA1 to agonists such as AITC, cinnamaldehyde, and
likely endogenous agonists. Activation of phospholipase C
(PLC) appears to be required for such GPCR-mediated
TRPA1 sensitization (with the exception ofMrgprA3), though
in the case of bradykinin receptor, protein kinase A (PKA)
may play a role as well (Wang et al. 2008a). PLC likely sen-
sitizes TRPA1 by removal of the inhibitory effect of PIP2 (Dai
et al. 2007; Wang et al. 2008a) and by IP3-dependent release
of calcium from intracellular stores (Jordt et al. 2004) (Fig. 2).
Protein kinase C (PKC) appears not to play a role in
bradykinin-dependent modulation of TRPA1 since neither
GF109203X, a potent inhibitor of PKC, nor phorbol 12-
myristate 13-acetate (PMA), a well-known PKC activator, al-
ters bradykinin-mediated TRPA1 sensitization (Wang et al.
2008a). Nonetheless, PKC seems necessary for TGR5-
dependent activation of TRPA1 (Lieu et al. 2014). MrgprA3
is activated by chloroquine and involved in histamine-
independent itch. It signals through Gβγ, as gallein, a small-
molecule inhibitor of Gβγ, markedly reduced chloroquine-
evoked calcium influx in cultured DRG neurons, whereas
U73122, a PLC inhibitor, had no effect (Wilson et al. 2011).
A similar Gβγ dependence has been observed in the case of
TGR5-dependent TRPA1 activation as well (Lieu et al. 2014).
Mechanical sensitivity
Soon after its discovery, TRPA1 was proposed as a
mechanosensor since its long ankyrin repeat could form a
spring-like structure to sense mechanical forces (Howard
and Bechstedt 2004; Sotomayor et al. 2005). In fact, it was
brought forward early on as a candidate for the long sought-
after tip-link mechanotransducer channel in hair cells of the
inner ear (Corey et al. 2004). However, this idea was
dismissed due to normal hair cell function and auditory func-
tion in TRPA1 KO mice (Bautista et al. 2006; Kwan et al.
2006). Direct mechanical stimulation of DRG neurons evokes
currents that can be characterized as rapidly adapting, inter-
mediate-adapting, and slowly adapting. Analysis of such cur-
rents from DRGs obtained from either WT and TRPA1 KO
mice has yielded inconsistent results with one group showing
a complete loss of slow-adapting currents, but not
intermediate- or rapidly adapting currents from IB4-negative
DRG neurons (Vilceanu and Stucky 2010), and another group
showing a small but significant effect on intermediate-
adapting currents from small-diameter DRGs with no effect
on slowly adapting currents. Further evidence for direct
mechanosensitivity of TRPA1 has been obtained from
TRPA1-expressing HEK293 cells where membrane shrinkage
(via hypertonicty) and membrane curvature (via
trinitrophenol) appear to activate TRPA1 (Hill and Schaefer
2007; Zhang et al. 2008). Most recently, it was shown that
lipopolysaccharide (LPS), an abundant outer membrane
glycolipid released by Gram-negative bacteria, activates en-
dogenously expressed and heterologously expressed TRPA1
channels (Meseguer et al. 2014). The activation depends on
the shape of membrane-anchoring lipid moiety of LPS,
indicating that perturbation of the plasma membrane may
underline channel activation. Hypertonicity, trinitrophenol,
and LPS may serve to sensitize TRPA1 channel despite
that fact that their direct effects on TRPA1 are relatively
small compared to those of electrophilic agonists (e.g.,
AITC). More research in this area will be needed to better
understand whether TRPA1 is indeed acting as a direct
mechanosensor.
In vitro skin–nerve preparation recordings indicate that
TRPA1 gene KO and treatment with the TRPA1 antagonist
HC-030031 can reduce mechanically induced action potential
firing in dermal C-fibers (Kerstein et al. 2009; Kwan et al.
2009). A similar reduction in action potential frequency was
observed in recordings of mechanosensitive visceral afferents
from the colon (Brierley et al. 2009). Furthermore, the in-
creased mechanical sensitivity observed in the skin–nerve
preparation following CFA could be reversed by HC-030031
(Lennertz et al. 2012). In vivo electrophysiology recordings
showed that A-967079 reduced the responsiveness of spinal
wide dynamic range (WDR) and nociceptive-specific neurons
to high-intensity mechanical stimuli in naïve and inflamed rats
(McGaraughty et al. 2010). However, A-967079 only affected
low-intensity mechanical stimuli-evoked responses in in-
flamed but not naïve rats.
Behavioral studies of acute mechanical nociception of
TRPA1 KO mice have shown rather inconsistent results.
Two early studies revealed no apparent deficit in acute me-
chanical nociception in KO mice (Bautista et al. 2006; Petrus
et al. 2007), while deficits were detected in other studies
(Kwan et al. 2006; Garrison and Stucky 2014; Minett et al.
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2014). In particular, Minett et al. compared KO mouse strains
of Nav1.3, Nav1.7, Nav1.8, Nav1.9, and TRPA1 and found
that only TRPA1 KO mice had a defect in mechanical
nociception as measured using the Randall-Selitto test applied
to the paw (Minett et al. 2014). Interestingly, TRPA1 KOmice
showed normal mechanical nociception using the same test
applied to the tail (where both Nav1.7 and Nav1.8 KO mice
displayed a clear defect). Finally, the deficit in acute mechan-
ical sensitivity observed in TRPA1 KOmouse should be care-
fully interpreted since a recent study showed a significant
reduction in intraepidemal nerve fiber density in TRPA1 KO
compared to wild-type mice (Andersson et al. 2013).
Cold sensitivity
Activation of TRPA1 by cold (temperature <17 °C) has been
shown by some groups (Bandell et al. 2004; Sawada et al.
2007; Karashima et al. 2009; del Camino et al. 2010; Lehto
et al. 2013) but disputed by others (Jordt et al. 2004; Zurborg
et al. 2007; Cordero-Morales et al. 2011). Efforts to resolve
the discrepancy were confounded by differences in experi-
mental procedures, including methodologies (Ca2+ imaging,
whole-cell or single-channel recordings), ionic conditions
(with or without extracellular Ca2+), and clones from different
species (human, rat, and mouse). In a recent study, TRPA1
from four different mammalian species were characterized
under the same experimental conditions (Chen et al. 2013).
In Ca2+-influx assays as well as whole-cell and single-channel
recordings, cold activates rat and mouse TRPA1, albeit with
lower efficacy compared to AITC (~40 % open-probability
relative to AITC). In contrast, neither human nor rhesus mon-
key TRPA1 could be activated by cold. These findings are in
line of most of the literature data and suggest that previous
discrepancies could be due to species differences. However,
cold activation of human TRPA1 has been observed in whole-
cell recordings by some groups (Bandell et al. 2004;
Kremeyer et al. 2010), and human TRPA1 reconstituted into
lipid bilayers is intrinsically cold-sensitive (Moparthi et al.
2014). Therefore, whether TRPA1 is a cold-sensitive channel
is not formally settled. At behavioral level, at least five studies
using TRPA1 KO mice produced conflicting results. Two
studies found that TRPA1KOmice retained normal responses
in cold plate and acetone-evoked evaporative cooling tests and
upon cold stimulation maintained normal c-fos expression (a
marker for neural activity) (Bautista et al. 2006; Knowlton
et al. 2010). A third study reported that female, but not male,
KO mice had reduced cold sensitivity (Kwan et al. 2006). A
fourth study reported that TRPA1 KO mice had no deficit in
acute cold sensation but lost the jumping behavior when chal-
lenged with prolonged cold exposure (Karashima et al. 2009).
The fifth study found no difference in cold sensitivity between
wild-type and KO mice but found that cold enhanced the
effects of AITC, thereby contributing to AITC-induced cold
allodynia (del Camino et al. 2010). In pharmacology studies
using TRPA1 antagonists, A-967079 did not affect acute cold
sensing in uninjured mice but attenuated cold allodynia in
neuropathic rats (Chen et al. 2011a). Similarly, HC-030031
was shown to attenuate cold hyperalgesia in CFA (inflamma-
tory), spared never injury (SNI, neuropathic), and paclitaxel-
mediated cold hyperalgesia (del Camino et al. 2010;
Materazzi et al. 2012). Additionally, TRPA1-specific anti-
sense oligodeoxynucleotides were efficacious in attenuating
cold allodynia in inflammatory and neuropathic pain models
(Obata et al. 2005). Taken together, these results suggest that
TRPA1 might not play a significant role in acute cold sensa-
tion but may be involved in cold allodynia under disease states
where endogenous TRPA1 activation mechanisms are
present.
Intriguingly, TRPA1 knockout mice showed higher toler-
ance to heat, higher heat threshold of cutaneous C-mechano-
heat-sensitive fibers, and less heat-induced CGRP release
(Hoffmann et al. 2013). Also HC-030031 was found to de-
crease heat hyperalgesia in the paclitaxel model of
chemotherapy-induced neuropathic pain (Chen et al. 2011b).
These effects might be due to TRPA1 sensitization, instead of
direct activation by heat. Unlike their counterparts in inverte-
brate and ancestral vertebrates, mammalian TRPA1 channels
are not activated by heat directly (Chen et al. 2013).
Physiological and pathological role of TRPA1
Pain
Several lines of evidence suggest that TRPA1 is involved in
pain sensation. TRPA1 is expressed in sensory neurons and
co-localized with pain markers such as TRPV1 and bradyki-
nin receptors (Obata et al. 2005; Bautista et al. 2006). Its
expression is increased in animal models of inflammatory
and neuropathic pain and in human avulsion-injured DRG
neurons (Obata et al. 2005; Anand et al. 2008). TRPA1 ago-
nists evoke neurotransmitter release, pain, and inflammation
in rodents and humans (Namer et al. 2005; Bautista et al.
2006; Kwan et al. 2006), and endogenous agonists such as
4-HNE are elevated under human pathologies (Morquette
et al. 2006). Gene KO attenuates agonist sensitivity, and an-
tagonist treatment attenuates pain in several animal models
(Bautista et al. 2006; Kwan et al. 2006; McNamara et al.
2007; Petrus et al. 2007; Eid et al. 2008; Chen et al. 2011a).
Recently, a TRPA1 gain of function mutation was linked to
human congenital pain condition called familial episodic pain
syndrome (FEPS) (Kremeyer et al. 2010). Based on data in the
literature, TRPA1 has been suggested to play a role in many
sensory modalities, including chemical nociception, mechan-
ical nociception, and cold nociception.
Among various sensory modalities, the best-established
and least controversial is chemical nociception. TRPA1
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detects a variety of exogenous noxious chemicals such as
AITC, cinnamaldehyde, allicin, and acrolein. The response
of DRG neurons to these compounds and the nocifensive be-
haviors they elicit have been rigorously demonstrated to be
TRPA1-dependent after TRPA1 KOmice became available in
2006 (Bautista et al. 2006; Kwan et al. 2006). The same level
of rigor has been applied to identify endogenous agonists as
well, clearly establishing that endogenous agonist-dependent
DRG calcium influx and nocifensive behaviors are TRPA1
dependent. Less clear, however, is the role that these endoge-
nous activators play in inflammatory and/or neuropathic pain
states. For example, while injection of the glucose metabolite
methlyglyoxal (MG) results in a TRPA1-dependent sensory
neuropathy in mice (Eberhardt et al. 2012; Andersson et al.
2013) and while MG is elevated in patients with diabetic neu-
ropathy, it has not yet been demonstrated that MG or TRPA1
plays a causative role of any kind in diabetic neuropathy.
Similarly, while many other endogenous activators of
TRPA1 (e.g., 4-HNE and acrolein) have been found to be
sufficient in causing pain behavior in rodents, there is current-
ly no evidence that these molecules play a causative role in
any form of inflammatory or neuropathic pain.
TRPA1 has also been proposed to play a role in mechanical
allodynia following induction of inflammatory and neuropath-
ic pain, indicating that TRPA1 might be a potential target for
novel chronic pain drugs. Early reports on the phenotype of
the TRPA1KOmouse indicated that there is little if any defect
in mechanical allodynia following either CFA-induced in-
flammatory pain or nerve injury-induced mechanical
allodynia (Kwan et al. 2006; Petrus et al. 2007). However,
more recent TRPA1 KO experiments appear to show a major
defect in CFA-induced inflammatory pain in the TRPA1 KO
mouse, however, especially in older mice (Garrison and
Stucky 2014). Also, while Petrus et al. 2007 failed to find a
defect in the CFA model in the TRPA1 KO mouse, they were
able to show that the TRPA1 blocker AP-18 was able to re-
verse CFA-induced inflammatory pain in WT mice but not in
TRPA1KOmice, indicating that indeed TRPA1 contributes to
CFA-induced mechanical allodynia and perhaps some form of
compensation occurs in the TRPA1 KO mouse allowing a
TRPA1-independent CFA-response in these animals. Other
TRPA1 antagonists such as HC-030031 have shown similar
attenuation of mechanical allodynia in the CFA model (Petrus
et al. 2007; Eid 2009). Intrathecally administered
Chembridge-5861528 attenuated mechanical hypersensitivity
in spinal nerve ligation model and capsaicin-induced second-
ary hyperalgesia model (Wei et al. 2011). However, some
newer generation TRPA1 antagonists with more robust expo-
sure (free plasma concentration vs. in vitro IC50) (Fig. 3) were
not effective in thesemodels despite showing robust inhibition
of AITC-induced nocifensive behavior. For example, A-
967079 at IC85 coverage did not attenuate mechanical
hyperalgesia in CFA, chronic constriction injury, or spinal
nerve ligation models (Chen et al. 2011a). AMG0902 at an
even higher drug exposure (fourfold over IC90 coverage) had
only a modest effect on mechanical allodynia in CFA model
and no effect in the spinal nerve ligation (SNL) model (Lehto
et al. 2013). On the other hand, potent inhibitors from
Glenmark Pharmaceutical Ltd. as well as the recently reported
potent inhibitor from Novartis (Novartis compound 31 in
Fig. 3) did appear to show efficacy in the CFA model
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Fig. 3 Examples of TRPA1
antagonists. HC-030031, AP18,
and A-967079 are currently the
most commonly used TRPA1 tool
antagonists for studying TRPA1
biology in vivo and in vitro. A
newer generation of TRPA1
antagonists (lower row) have
recently been developed that offer
better potency on the rodent
TRPA1 channels as well as
significantly improved PK
properties compared to earlier
generation compounds
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Several groups have demonstrated a role for TRPA1 in
rodent models of chemotherapy-induced painful neuropathy
(CIPN) and painful diabetic neuropathic (PDN). These two
forms of neuropathic pain are of particular interest since they
can be directly studied in early proof-of-concept clinical trials
in humans. As shown using either TRPA1 KO mice or the
TRPA1 antagonist HC-030031, TRPA1 appears to contribute
significantly to paclitaxel-induced mechanical allodynia
(Materazzi et al. 2012) as well as bortezomib- and
oxaliplatin-induced mechanical allodynia (Trevisan et al.
2013a) in mice. Strikingly, block of TRPA1 during the 5-h
period encompassing the time of bortezomib dosing appears
to completely prevent the development of neuropathic pain in
this model (Trevisan et al. 2013a). In the case of DPN, no
published data exists showing whether or not the development
of diabetic neuropathic pain is impaired in TRPA1 KO mice.
However, intrathecal injections of the TRPA1 antagonist
CHEM-5861528 have been found to reverse mechanical
allodynia in streptozotocin-induced diabetic rats (Wei et al.
2009; Wei et al. 2010) and may prevent diabetes-induced loss
of nociceptor nerve endings in the skin (Koivisto et al. 2012).
More recently, Glenmark Pharmaceuticals Ltd. reported that
GRC 17536, a peripheral acting TRPA1 antagonist, exhibited
efficacy in a phase 2a proof-of-concept study in patients with
painful diabetic neuropathy.
TRPA1 is present in nociceptive fibers innervating internal
organs (e.g., colon and pancreas) and implicated in visceral
pain and inflammation. When activated during inflammation,
these fibers carry visceral pain signals and also release neuro-
peptides such as substance P and CGRP, resulting in neuro-
genic inflammation. Desensitization of TRPV1 receptor-
expressing C-fibers using treatment with either resiniferatoxin
(RTX) or capsaicin results in significantly reduced severity of
dextran-sulfate-sodium (DSS)-induced colitis in mice (Kihara
et al. 2003; Engel et al. 2012), indicating that TRPV1-positive
nociceptor fibers are involved in this model of colitis.
Furthermore, DSS-induced colitis was found to be ameliorat-
ed in both CGRP KO mice and substance P KO mice (Engel
et al. 2012). TRPV1 itself does not appear to play a role in
either DSS-induced colitis or trinitrobenzene-sulfonic-acid
(TNBS)-induced colitis as these models are not altered in the
TRPV1 KO mouse (Engel et al. 2011; Engel et al. 2012).
However, both DSS-induced and TNBS-induced colitis were
significantly reduced in TRPA1 KO mice or WT mice treated
with the TRPA1 antagonist HC-030031. Similar data have
been obtained in the case of caerulein-induced pancreatitis,
where TRPA1 antagonists and genetic removal of TRPA1
(TRPA1 KO mouse) have been shown to reduce the extent
of inflammation and pain in this model (Ceppa et al. 2010;
Schwartz et al. 2011; Schwartz et al. 2013).
Spinal activation of TRPA1 may contribute to pain and
represents a target for pharmacological intervention (Wei
et al. 2011). However, a recent study suggests that spinal
TRPA1 activation may underlie the antinociceptive effect of
acetaminophen (Anderson et al. 2011). It was shown that re-
active metabolites of acetaminophen can directly activate
TRPA1 at the central terminals of primary sensory neurons,
causing inactivation of voltage-gated Ca2+ and Na+ channels
and thereby reducing neurotransmitter release and neuronal
excitability. The antinociceptive effect of spinal TRPA1 acti-
vation does not appear limited to covalent TRPA1 agonists, as
Δ9-tetrahydrocannabiorcol, a noncovalent agonist, is also
antinociceptive in the hot plate test. Thus, spinal activation
of TRPA1 can be either nociceptive or antinociceptive, per-
haps depending on the degree of TRPA1 activation.
Therefore, it is possible that both antagonists and agonists of
TRPA1 may have utility for pain relief.
Respiratory diseases
TRPA1 is expressed in primary sensory neurons innervating
the airways where it acts as a chemosensor for airway irritants
such as acrolein, ozone, isocyanate, tear gas, and chlorine
(Andre et al. 2008; Bessac et al. 2008; Bessac et al. 2009).
TRPA1 activation leads to pain and reflex (sneezing, cough,
and respiratory depression and avoidance), therefore serves as
a protection to limit or eliminate irritant exposure. TRPA1 can
also be activated chronically in chronic cough, asthma, chron-
ic obstructive pulmonary disease (COPD), and rhinitis, where-
in endogenous TRPA1 ligands (e.g., 4HNE, H2O2) and pro-
inflammatory mediators (e.g., bradykinin and nerve growth
factors) are elevated (Dolovich et al. 1970; Winterbourn and
Kettle 2000). These ligands activate TRPA1 directly (e.g.,
4HNE and H2O2), indirectly (bradykinin), or by increasing
TRPA1 surface expression (nerve growth factor).
Reciprocally, heightened TRPA1 function leads to neurotrans-
mitter release and promotes neurogenic inflammation (Andre
et al. 2008; Caceres et al. 2009).
The role of TRPA1 in airway pathologies has been corrob-
orated by studies using the TRPA1 KO mouse and TRPA1
antagonists. In wild-type mice, airway exposure to hypochlo-
rite or H2O2 evoked respiratory depression as manifested by a
reduction in breathing frequency and increase in end expira-
tory pause, both of which were attenuated in TRPA1 KOmice
(Bessac et al. 2008). In an ovalbumin-induced mouse asthma
model, gene KO and treatment with HC-030031 reduced the
induction of cytokines, chemokines, neurotransmitters, as
well as leukocyte infiltration and airway hyperactivity
(Caceres et al. 2009). In the guinea pig, acrolein,
crotonaldehyde, and extracts from cigarette smoke induced
neurotransmitter release, tracheal plasma extravasation, and
bronchi contraction. These effects could be attenuated by
HC-030031 (Andre et al. 2008). These results are certainly
encouraging, although it is worth noting that chronic respira-
tory diseases are multifaceted disorders, often involving air-
way damage and tissue remodeling. It remains to be
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demonstrated whether TRPA1 antagonists are capable of re-
versing disease progression and outperforming current stan-
dard of care such as anti-inflammatory drugs and
bronchodilators.
Itch
Recent studies suggest that TRPA1 is involved in mediating
histamine-independent itch (Wilson et al. 2011; Wilson et al.
2013a). The antimalarial drug chloroquine and the endoge-
nous pruritogen BAM8-22 induce itch through Mas-related
G protein-coupled receptors (MrgprA3 and MrgprC11, re-
spectively), and their effect is mediated through TRPA1. In
lesioned skin of human atopic dermatitis patients, TRPA1 ex-
pression is increased in dermal afferent fibers, dermal cells,
and mast cells (Oh et al. 2013). In a mouse model of atopic
dermatitis generated by overexpression of IL-13, TRPA1 ex-
pression is also increased in afferent fibers, dorsal root gan-
glia, and mast cells in a manner similar to that observed in
human patients (Oh et al. 2013). Furthermore, HC-030031
and genetic deletion of mast cells attenuated itch-scratching
behaviors. In oxazolone-induced contact dermatitis models,
TRPA1 KO and HC-030031 decreased pro-inflammatory cy-
tokines, T cell infiltration, dermatitis score, and edema, indi-
cating that TRPA1may play a central role in inflammation and
pruritus (Liu et al. 2013).
Antagonist tools
An increasing number of TRPA1 antagonists have been
disclosed, and only a few examples are listed here (Fig. 3).
HC-030031, a xanthine alkaloid discovered by Hydra
Bioscience, has been the most widely used in the literature
as a tool for studying TRPA1-mediated biology (McNamara
et al. 2007; Eid et al. 2008). HC-030031 inhibits human and
rat TRPA1 with IC50 of 6.2 and 7.6 μM, respectively
(McNamara et al. 2007; Bianchi et al. 2012). It is selective
against several TRP channels (IC50 >10 or 20 μM). However,
when tested in radioligand binding assays at 10 μM concen-
tration, HC-030031 showed activity against several proteins
including sodium channels (40 %) and sigma receptors (37 %)
(Chen et al. 2011a). In addition, HC-030031 has high clear-
ance (27 ml/kg/min), low exposure (Cmax=355 ng/ml fol-
lowing a 12-mg/kg dose), a short half-life (32 min), and high
plasma protein binding (90 %) in rats (Rech et al. 2010). With
such poor pharmacokinetic (PK) properties, it is unlikely that
HC-030031 can reach unbound concentrations above the
TRPA1 IC50 even at very high doses. Nonetheless, it exhibited
efficacy in CFA, SNL, and other pain models (McNamara
et al. 2007; Petrus et al. 2007; Eid et al. 2008). The efficacy
of HC-030031 has not been conclusively attributed to the
block of TRPA1 by showing, for example, that efficacy is lost
in the TRPA1 KO mouse, and therefore, results obtained with
this low-potency compound should be interpreted with
caution.
Recently, Abbott, Amgen, AstraZenica, Glenmark, Hydra
Bioscience, Janssen, Merck, and other companies have
disclosed additional TRPA1 antagonists with improved poten-
cy, selectivity, and pharmaceutical properties (Fig. 3).
Pharmacokinetic and efficacy data have been described for
A-967079 (Abbott) , Compound 10 (Amgen), and
Compound 31 (Novartis) (Chen et al. 2011a; Copeland et al.
2014; Rooney et al. 2014). Compound 10, an azabenzofuran
analog, inhibits human and rat TRPA1 with IC50 of 0.17 and
0.045 μM, respectively, and has favorable PK properties
allowing robust unbound plasma exposure (14-fold over rat
IC50 when dosed at 100 mg/kg). This compound was highly
efficacious in the AITC-flinch model, but its efficacy in other
pain models was not reported (Copeland et al. 2014). This
new generation of TRPA1 antagonists will be valuable in ex-
ploring TRPA1 function and therapeutic utility and will hope-
fully replace the use of older TRPA1 tool compounds.
Beside small molecules, monoclonal antibodies (mAbs)
have been generated using a cell immunogen approach (Lee
et al. 2014). The most potent mAb, 2B10, inhibited activation
by AITC (IC50, 260 nM), cold (IC50, 90 nM), and hypertonic-
ity (IC50, 350 nM). 2B10 also had similar effect on mouse
TRPA1, and therefore, it likely targets a domain conserved
in human and mouse channels, probably in the extracellular
pore loop. Similar to pore-blocking antibodies for other ion
channels, the inhibition of TRPA1 plateaued at 70 %. 2B10
might be a potentially useful tool if it can get access to relevant
tissues.
Species differences
The electrophile sensitivity of TRPA1 is conserved across
species (e.g., fruit fly, lizard, snake, chicken, mouse, and
humans), indicating electrophile detection is a core function
of TRPA1. On the other hand, TRPA1 also exhibits evolution-
ary divergence in temperature sensitivities, from being heat-
sensitive in invertebrates/ancestral vertebrates (fruit fly, rattle
snake, lizard, and frog) (Viswanath et al. 2003; Hamada et al.
2008; Kwon et al. 2008; Gracheva et al. 2010; Kang et al.
2012), to being cold-sensitive in rodents (Story et al. 2003;
Chen et al. 2013), and to being temperature-insensitive in
primates (Jordt et al. 2004; Chen et al. 2013). The evolution-
ary divergence in thermo-sensitivity indicates the likelihood
that TRPA1 from different species (e.g., human and rats) may
have different functions. At the amino acid level, human and
rat TRPA1 are poorly conserved (79 % identical, compared to
94 % for TRPM8 and 86 % for TRPV1 for examples), which
may lead to qualitative or quantitative differences in sensitiv-
ity to ligands. Additionally, other cross-species variations
(metabolic mechanisms, transduction pathways, and animal
physiology) can lead to species difference of TRPA1 function.
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Species difference in response to pharmacological agents
has been well demonstrated for TRPA1 (Bianchi et al. 2012).
For example, thioaminols and caffeine activate rodent chan-
nels but block the human channel (Klionsky et al. 2007; Chen
et al. 2008; Nagatomo et al. 2010). Menthol activates the
human channel at high concentration but blocks rodent chan-
nels (Xiao et al. 2008). In high throughput screening and me-
dicinal chemistry efforts, we and others have found that a
majority of human TRPA1 antagonists have reduced potency,
or act as agonists, on the rodent TRPA1 channels. Such com-
pounds could not be advanced in the drug discovery process
due to the need to use rodents as preclinical species. Recently,
we showed that monkey and human TRPA1 share similar
pharmacology and therefore monkey could potentially serve
as a surrogate species (Bianchi et al. 2012). However, the
practical use of monkeys is hindered by high cost, low
throughput, and the limited number ofmonkey diseasemodels
available. The generation of humanized transgenic animals
(i.e., knocking-in of human TRPA1) could be a valuable al-
ternative path forward. In all, species difference is a serious
problem and requires creative solutions.
Potential adverse effects
Although TRPA1 is predominantly expressed in sensory neu-
rons, it is also expressed in other tissues. Therefore, targeting
TRPA1 could have unintended adverse effects. TRPA1 KO
mince appear normal in appearance, reproduction, and audi-
tory function (Bautista et al. 2006; Kwan et al. 2006), although
physical hyperactivity was recently reported (Bodkin et al.
2014). Unlike TRPV1 or TRPM8, TRPA1 is not involved in
body temperature regulation at basal level or under cold chal-
lenge (Chen et al. 2011a; de Oliveira et al. 2014), and there-
fore, TRPA1 antagonists should be devoid of the adverse ef-
fects associated with TRPV1 antagonists (hyperthermia) or
TRPM8 antagonists (hyperthermia).
One potential safety concern for TRPA1 antagonists is the
deficit in sensing environmental irritants. Activation of
TRPA1 by acrolein, ozone, and chlorine leads to pain, mucus
secretion, sneezing, cough, and respiratory depression
(Bautista et al. 2006; Andre et al. 2008; Bessac et al. 2008;
Kwan et al. 2009). These nociceptive and behavioral re-
sponses help limit or eliminate irritant exposure, therefore
protecting the body from damage. As an example, chlorine
is widely used as a domestic (disinfection) and industry prod-
uct with an annual consumption of 15million tons in the USA.
While most individuals can react quickly to avoid severe ex-
posure, injuries do occur in the form of pulmonary edema,
restrictive lung diseases, and obstructive disease. Airway ex-
posure of chlorine results in reduced breathing frequency and
increased end expiratory pause in wild-type mice, but such
protective reflexes are absent in KO mice (Bessac et al.
2008). Will TRPA1 antagonists cause deficits in sensing and
avoiding irritants in humans? This question should be ad-
dressed during clinical development.
Concluding remarks
In the TRP family and ion channel superfamily as a whole,
TRPA1 distinguishes itself by its covalent activation mecha-
nism and its role in sensing a wide range of noxious
chemicals. TRPA1 is also one of the few ion channels impli-
cated in pain by human genetics. A large body of evidence
supports the therapeutic utility of TRPA1 antagonists for pain,
respiratory, itch, and other diseases. Additionally, TRPA1 an-
tagonists appear not to cause significant safety concerns thus
far. As such, TRPA1 has replaced TRPV1 as one of the most
sought-after therapeutic targets for novel pain drugs. In
September 2014, Glenmark announced that GRC 17536, a
peripherally acting selective TRPA1 antagonist, exhibited ef-
ficacy in a phase 2a proof-of-concept study in patients with
painful diabetic neuropathy. Despite this clear progress, there
are many unanswered questions. Is TRPA1 a receptor for nox-
ious cold? Does it play a role in mechosensation?What are the
endogenous ligands? Do TRPA1 KO mice tell the full story?
Do TRPA1 have cross-species difference in physiological and
pathological function? What are the best therapeutic indica-
tions for TRPA1 antagonists? Do TRPA1 antagonists cause
deficits in sensing noxious irritants? Recognizing and address-
ing these questions will not only reveal the physiological func-
tion of TRPA1 but also pave the way for developing new
therapies.
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